[go: up one dir, main page]

MX2010006310A - O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. - Google Patents

O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.

Info

Publication number
MX2010006310A
MX2010006310A MX2010006310A MX2010006310A MX2010006310A MX 2010006310 A MX2010006310 A MX 2010006310A MX 2010006310 A MX2010006310 A MX 2010006310A MX 2010006310 A MX2010006310 A MX 2010006310A MX 2010006310 A MX2010006310 A MX 2010006310A
Authority
MX
Mexico
Prior art keywords
desmethyl
venlafaxine
depressive disorder
major depressive
treating major
Prior art date
Application number
MX2010006310A
Other languages
English (en)
Inventor
Robert Michael Poole
Karen Astrid Tourian
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2010006310A publication Critical patent/MX2010006310A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención provee métodos para tratar el trastorno depresivo mayor (MDD, por sus siglas en inglés); en general, los métodos comprenden administrar a un paciente que lo necesita una dosis diaria de aproximadamente 50 mg de o-desmetil-venlafaxina (ODV) o una cantidad equivalente de una sal farmacéuticamente aceptable de la misma; en ciertas modalidades, un paciente que necesita tratamiento se caracteriza por un diagnóstico primario de MDD; en algunas modalidades, la dosis se administra como una sola dosis diaria; en un conjunto de modalidades, los métodos incluyen administrar una forma de dosis oral que comprende sal de succinato de ODV.
MX2010006310A 2007-12-10 2007-12-10 O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. MX2010006310A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/086986 WO2009075677A1 (en) 2007-12-10 2007-12-10 O-desmethyl-venlafaxine for treating major depressive disorder

Publications (1)

Publication Number Publication Date
MX2010006310A true MX2010006310A (es) 2010-08-31

Family

ID=39326191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006310A MX2010006310A (es) 2007-12-10 2007-12-10 O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.

Country Status (7)

Country Link
US (1) US20110027324A1 (es)
AU (1) AU2007362336A1 (es)
BR (1) BRPI0722303A2 (es)
CA (1) CA2708832A1 (es)
MX (1) MX2010006310A (es)
TR (1) TR201004720T1 (es)
WO (1) WO2009075677A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012024576A2 (pt) * 2010-03-31 2016-05-31 Wockhardt Ltd composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição
CA2788526A1 (en) * 2010-05-14 2011-11-17 Alembic Limited Extended release formulations of desvenlafaxine base
US20200000229A1 (en) * 2018-06-28 2020-01-02 Summit Product Development, LLC Low Profile Cabinet Organizer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008000249A (es) * 2005-07-06 2008-03-18 Sepracor Inc Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
RU2007148195A (ru) * 2005-07-15 2009-08-20 Вайет (Us) Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением

Also Published As

Publication number Publication date
BRPI0722303A2 (pt) 2014-04-22
CA2708832A1 (en) 2009-06-18
WO2009075677A1 (en) 2009-06-18
AU2007362336A1 (en) 2009-06-18
US20110027324A1 (en) 2011-02-03
TR201004720T1 (tr) 2010-11-22

Similar Documents

Publication Publication Date Title
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
NZ604029A (en) Methods of treating bladder cancer
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
IL189546A0 (en) Therapy for the treatment of disease
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
IL196425A (en) Dosage unit for oral administration containing ibuprofen and pamotidine
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2013127420A (ru) Способы уменьшения психогенного или компульсивного переедания
RU2012108439A (ru) Способы лечения опухолей головного мозга
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
JP2008534503A5 (es)
MX2013003523A (es) Composicion farmaceutica de dosis baja.
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal